Form 8-K - Current report:
SEC Accession No. 0001641172-25-017052
Filing Date
2025-06-30
Accepted
2025-06-30 08:05:16
Documents
14
Period of Report
2025-06-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41251
2 EX-99.1 ex99-1.htm EX-99.1 16866
  Complete submission text file 0001641172-25-017052.txt   281223

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bfri-20250630.xsd EX-101.SCH 3975
4 XBRL DEFINITION FILE bfri-20250630_def.xml EX-101.DEF 26989
5 XBRL LABEL FILE bfri-20250630_lab.xml EX-101.LAB 37209
6 XBRL PRESENTATION FILE bfri-20250630_pre.xml EX-101.PRE 25609
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6811
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 251088809
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)